Pfizer to acquire Biohaven

Wednesday 18 May 2022

United States

Pfizer Inc is to spend $11.6 billion to acquire the US biopharmaceutical company Biohaven Pharmaceuticals Inc in a move that will bolster its neurology assets and give it an approved product for migraine. Announced on 10 May, the deal is Pfizer’s second in recent weeks as the company takes advantage of its Covid-19 vaccine revenues to expand its business. In early April, Pfizer announced plans to spend $525 million to acquire ReViral Ltd, a UK concern with candidate products for respiratory syncytial virus infection.